Mendus cancer vaccine succeeds in Phase II AML trial

Mendus presented positive new clinical data from a Phase II clinical trial investigating vididencel as a maintenance treatment in acute myeloid leukaemia (AML). Sweden-based biopharma company announced the results at the European Hematology Association (EHA) 2023 Hybrid Congress.